GEN Reports on Advances in Regenerative Medicine

April 2, 2012 - PRLog -- Contact: John Sterling, Ph. 914-740-2196, jsterling@genengnews.com

GEN Reports on Advances in Regenerative Medicine

New Rochelle, NY—Scientists carrying out studies on stem cells and regenerative medicine are employing a broad range of approaches in the quest to develop novel therapeutic products, reports Genetic Engineering & Biotechnology News (GEN) (http://www.genengnews.com). In light of last year’s U.S. Appeals Court ruling that overturned a ban on federal funding for stem cell research, investigators now believe that the pace of new discoveries in regenerative medicine will quickly pick up, according to the latest issue of GEN. (http://genengnews.com/gen-articles/regenerative-medicine-looks-to-the-future/4059)

“While the former ban on federal funding for stem cell research negatively impacted research efforts, many scientists relied on innovative strategies to move the regenerative medicine field forward,” said John Sterling, Editor in Chief of GEN.

For example, novel cell lines involving pure pluripotent embryonic progenitors and “smart” allogenic adult stem cells have been created. New ultrasonic cavitation techniques for the safe, effective separation of the stromal vascular fraction have been devised and directional freezing methods for effective biopreservation of cellular tissue have been developed. In addition, high-pressurized, cultured autologous hyaline cartilage implants have been applied in the clinic.

The GEN article covers research on regenerative medicine taking place at BioTime, Xennex, Parcell Laboratories, Intellicell Biosciences, Core Dynamics, and Histogenics.

For a copy of the April 1 issue of GEN, please call (914) 740-2122, or email: ebicovny@liebertpub.com.

# # #

Genetic Engineering and Biotechnology News (http://www.genengnews.com) which is published 21 times a year by Mary Ann Liebert, Inc. (http://www.liebertpub.com), is the most widely read biotechnology news magazine worldwide. It includes articles on Drug Discovery, Bioprocessing, OMICS, Biobusiness, and Translational Medicine.